Esperion Therapeutics, Inc. (ESPR) Form 8-K — Jun 1, 2026
Esperion Therapeutics, Inc. (ESPR) held its 2026 annual meeting of stockholders on May 28, 2026, where shareholders approved an amendment to the company’s 2022 Stock Option and Incentive Plan. The amendment increases the aggregate number of shares authorized for issuance under the plan by 7,000,000 shares, bringing the total authorized pool to 30,150,000 shares. Shareholders also elected J.
Key figures
- Shares Outstanding
- 257404876
- Shares Added To Plan
- 7000000
- Shares Present At Meeting
- 177208856
- Shares Authorized For Plan
- 30150000
Price after filing
1 day: +0.3%7 days: +0.6%30 days: +1.0%
Close on the filing date to close N calendar days later (from $3.13). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.